Ablation of human skin mast cells in situ by lysosomotropic agents

• Published in: Experimental dermatology 2015-07, Vol.24 (7), p.516-521
• Main Authors: Hagforsen, Eva, Paivandy, Aida, Lampinen, Maria, Weström, Simone, Calounova, Gabriela, Melo, Fabio R., Rollman, Ola, Pejler, Gunnar
• Format: Article
• Language: English
• Subjects: apoptosis; Apoptosis - drug effects; Cell Count; Cell Proliferation - drug effects; Dipeptides - pharmacology; Fibroblasts - drug effects; Humans; Immunologi inom det medicinska området; Immunology in the medical area; Immunosuppressive Agents - pharmacology; In Vitro Techniques; Indoles - pharmacology; Keratinocytes - drug effects; LLME; Lysosomes - drug effects; Lysosomes - immunology; Lysosomes - pathology; lysosomotropic agents; mast cells; Mast Cells - drug effects; Mast Cells - immunology; Mast Cells - pathology; Mastocytosis, Cutaneous - drug therapy; Mastocytosis, Cutaneous - immunology; Mastocytosis, Cutaneous - pathology; siramesine; Skin - drug effects; Skin - immunology; Skin - pathology; Spiro Compounds - pharmacology
• ISSN: 0906-6705; 1600-0625; 1600-0625
• DOI: 10.1111/exd.12699

Mast cells are known to have a detrimental impact on numerous types of inflammatory skin diseases such as contact dermatitis, atopic eczema and cutaneous mastocytosis. Regimens that dampen skin mast cell‐mediated activities can thus offer an attractive therapeutic option under such circumstances. As mast cells are known to secrete a large array of potentially pathogenic compounds, both from preformed stores in secretory lysosomes (granules) and after de novo synthesis, mere inhibition of degranulation or interference with individual mast cell mediators may not be sufficient to provide an effective blockade of harmful mast cell activities. An alternative strategy may therefore be to locally reduce skin mast cell numbers. Here, we explored the possibility of using lysosomotropic agents for this purpose, appreciating the fact that mast cell granules contain bioactive compounds prone to trigger apoptosis if released into the cytosolic compartment. Based on this principle, we show that incubation of human skin punch biopsies with the lysosomotropic agents siramesine or Leu‐Leu methyl ester preferably ablated the mast cell population, without causing any gross adverse effects on the skin morphology. Subsequent analysis revealed that mast cells treated with lysosomotropic agents predominantly underwent apoptotic rather than necrotic cell death. In summary, this study raises the possibility of using lysosomotropic agents as a novel approach to targeting deleterious mast cell populations in cutaneous mastocytosis and other skin disorders negatively influenced by mast cells.